Candidate Markers Associated with the Probability of Future Pulmonary Exacerbations in Cystic Fibrosis Patients

Gabriella Wojewodka1, Juan B. De Sanctis2, Joanie Bernier3, Julie Bérubé4, Heather G. Ahlgren5, Jim Gruber3, Jennifer Landry3, Larry C. Lands6, Dao Nguyen5, Simon Rousseau5, Andrea Benedetti5,7, Elias Matouk3, Danuta Radzioch1,5

1 Department of Human Genetics, McGill University, Montreal, Quebec, Canada, 2 Institute of Immunology, Central University of Venezuela, Caracas, Venezuela, 3 Adult Cystic Fibrosis Clinic, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada, 4 McGill University Health Center Research Institute, Montreal, Quebec, Canada, 5 Department of Medicine, McGill University, Montreal, Quebec, Canada, 6 Division of Pediatric Respiratory Medicine, Montreal Children’s Hospital, McGill University Health Center Research Institute, Montreal, Quebec, Canada, 7 Department of Epidemiology, Biostatistics and Occupational Health, Montreal Chest Institute, McGill University Health Center, Montreal, Quebec, Canada

Abstract

Introduction: Pulmonary exacerbations (PEs) cause significant morbidity and can severely impact disease progression in cystic fibrosis (CF) lung disease, especially in patients who suffer from recurrent PEs. The assessments able to predict a future PE or a recurrent PE are limited. We hypothesized that combining clinical, molecular and patient reported data could identify patients who are at risk of PE.

Methods: We prospectively followed a cohort of 53 adult CF patients for 24 months. Baseline values for spirometry, clinical status using the Matouk Disease Score, quality of life (QOL), inflammatory markers (C-reactive protein (CRP), interleukins (IL)-1β, -6, -8, -10, macrophage inflammatory protein (MIP)-1β, tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF)), polyunsaturated fatty acids and lipid peroxidation in blood plasma were collected for all patients during periods of stable disease, and patients were monitored for PE requiring PO/IV antibiotic treatment. Additionally, we closely followed 13 patients during PEs collecting longitudinal data on changes in markers from baseline values. We assessed whether any markers were predictors of future PE at baseline and after antibiotic treatment.

Results: Out of 53 patients, 37 experienced PEs during our study period. At baseline, we found that low lung function, clinical scoring and QOL values were associated with increased risk of PE events. PEs were associated with increased inflammatory markers at Day 1, and these biomarkers improved with treatment. The imbalance in arachidonic acid and docosahexaenoic acid levels improved with treatment which coincided with reductions in lipid peroxidation. High levels of inflammatory markers CRP and IL-8 were associated with an early re-exacerbation.

Conclusion: Our results demonstrate that worse clinical and QOL assessments during stable disease are potential markers associated with a higher risk of future PEs, while higher levels of inflammatory markers at the end of antibiotic treatment may be associated with early re-exacerbation.

Introduction

Cystic fibrosis (CF) patients often suffer acute exacerbations of their pulmonary symptoms, necessitating more aggressive treatment. Pulmonary exacerbations (PEs) are major events contributing to the morbidity and progression of CF lung disease. The recovery from PEs is largely based on the reversal of symptoms and improvement in lung function. However, pre-PE lung function levels are not recovered in 15% to 25% of CF patients[1,2]. Even when pulmonary function tests return to normal values, experiencing a PE contributes to long-term decline in lung disease with similar impacts on survival as would a 12% reduction in lung function[3,4]. Higher frequencies of PEs were associated with greater rates of decline in forced expiratory volume in one second percent predicted (FEV1%), especially having more than two PEs per year could increase the need for transplant and the risk of death[5]. The survival model characterized by Liou et al. also predicted that the impact on 5-year mortality of four PE.
events in a single year was as detrimental as *Burkholderia cepacia* infection or a 48% reduction in FEV1%[3]. Given the substantial morbidity and mortality associated with PEs, there is a urgent need to identify patients at risk of PE, particularly recurrent PEs. Improving the clinicians’ ability to stratify patients based on their risk to develop PEs will allow for more effective prevention (eg. treatment of CF related diabetes or allergic bronchopulmonary aspergillosis) and early intervention to prevent irreversible lung damage. Although standards of care that include inhaled antibiotics, azithromycin, recombinant human deoxyribonuclease and hypertonic saline contribute in reducing the frequency of exacerbations, there is currently no effective and reproducible diagnostic marker for the identification of early stages of PE. The standard criteria used to monitor PEs are mainly focused on lung function indicators such as FEV1% which are mostly reflective of disease severity and not necessarily disease activity[6]. Patient reported symptoms are important complements to physician-documented clinical signs in the diagnosis of PE. In fact, newly developed diaries are being validated for the purpose of early intervention to quickly reduce the development of a full and vigorous inflammatory response and to shorten and reduce the severity of PE with the hope of preventing the development of irreversible lung damage[7].

The events that trigger PEs are still poorly understood and may include respiratory viral infections[8,9] and air pollution[10]. Bacterial pathogens already present in the patients’ lungs may be causing PEs by adapting their virulence or colonizing new areas of the lung[11]. Retrospective studies have found risk factors for developing PEs which include the female sex, nutritional status, CF co-morbidities such as CF related diabetes, pancreatic insufficiency, and lung microbiology (eg. *Aspergillus fumigatus, Burkholderia cepacia*)[2,3,5,12,13]. Due to the nature of data available to perform retrospective analyses, these risk factors are based on clinical information which help to identify a population of CF patients more likely to have PEs. However on an individual basis, it remains difficult to assess which patients will experience a PE.

There have been few prospective studies looking at factors associated with risk of PEs which included molecular markers as predictors. A study by Sequeiros et al. found that the time to the next PE was shorter in patients with allergic bronchopulmonary aspergillosis and CF related diabetes. The authors also described that high C-reactive protein (CRP) and low FEV1 values at the end of antibiotic PE treatment were associated with shorter times until the next PE. They did not find any other molecular markers of significance[14]. Gray et al. demonstrated that serum calprotectin levels at the end of PF treatment rather than CRP were linked to the time until next PE[15]. These two studies show the potential of inflammatory markers in predicting risk of future PE.

For this study, we asked two questions: 1) In a period of stable disease, who is more likely to have a PE in the future? and 2) After PE treatment, who is at risk of an early re-exacerbation? We hypothesized that combining clinical and patient reported data with inflammatory markers and fatty acids may result in a better evaluation of patient disease activity. More specifically, we describe that worse disease-specific patient reported quality of life (QOL) and clinical assessments during stable disease indicated risk of PE, while higher levels of inflammation at the end of PE treatment were associated with early re-exacerbation.

### Materials and Methods

#### Study design

**Primary study: Markers at stable disease associated with risk of future PE.** CF patients from the Adult Cystic Fibrosis Clinic at the Montreal Chest Institute (Montreal, QC, Canada) were approached during their regular clinic visit to participate in the study. Fifty-three patients were enrolled in our prospective cohort study and were followed for a 12 month period from enrollment. The study duration was 24 months in total. Baseline data was recorded during a period of stable disease defined by the absence of any PE, requiring intravenous (IV) or oral antibiotic therapy in the preceding month. One patient was excluded from the study after baseline data was collected due to lung transplantation, thus we had 52 patients in our patient group. Inhaled antibiotics (tobramycin or aztreonam) were prescribed as maintenance therapy to 39 patients enrolled in the study (75% of the cohort: 32 patients that had PE and 7 that had no PE). A PE was defined as any change in patients’ symptoms (increased cough, sputum production and breathlessness, and decreases in lung function, weight, appetite and energy) requiring additional oral or IV antibiotic therapy [5].

The decision to treat was at the physicians’ discretion and was not influenced by this study. All patients were treated with β-lactams and/or fluoroquinolones in addition to tobramycin. Some received additional antibiotics such as doxycycline, clindamycin or trimethoprim. Nine patients were given corticosteroids during their first PE of the study based on previous response and/or severe bronchospasm.

**Secondary study: Markers at the end of PE treatment associated with early re-exacerbation.** Among patients that experienced PE (n = 37), we collected serial longitudinal clinical and blood samples throughout the PEs of 13 randomly selected patients. Data and samples were collected at Day 1 (within 24 hours prior to PE treatment, n = 13), and on follow-up assessments on Days 7 (n = 12), 14 (n = 11), 21 (n = 9) and 42 (n = 8). Four patients received treatment for 14 days and nine for 21 days. Patient compliance limited the sampling of all patients for Days 7, 14 and 21 time points. By Day 42, four patients had already re-exacerbated and were not included in this follow-up time point.

Volunteers serving as healthy controls (HC) were recruited from the McGill University Health Centre. CF patients and healthy controls gave written consent to participate in the study which was approved by the Institutional Review Board of the McGill University Health Centre.

#### Clinical data and clinical scoring

At enrollment, patients’ information on age, sex, weight and body mass index (BMI) was recorded. At baseline (n = 52) and at all defined time points during PEs (n = 8–13), the patients’ weight, BMI, complete blood cell counts and clinical information for the Matouk Disease Score were assessed. The Matouk Disease Score (Matouk Modified N. Huang Disease Score), previously described and validated[16,17], was used to quantify disease activity of CF patients. Briefly, the total score comprises of four subscores: Clinical (weight, weight change, dyspnoea, cough, sputum, physical exam, respiratory rate/breathing pattern/cardiac frequency, bacterial culture, appetite and general condition), Pulmonary Function (PFT: forced vital capacity percent predicted (FVC%), FEV1% predicted, FEV1/FVC, forced expiratory flow (FEF)25-75% predicted, FEF50% predicted, RV/TLC), Chest Radiography (CXR) score (based on the Bradfield method for radiography scoring, comprised of scores for air trapping, linear markings, nodular cystic lesions, parenchymal lesions, general

---

**Markers of Exacerbations in Cystic Fibrosis**
impression) and Complications score (number of previous PEs, pneumothorax, hemoptysis, respiratory failure, cardiac enlargement, pulmonary surgery). Healthier patients have higher scores for Clinical, PFT and CXR categories and lower values for the Complications score. To calculate the total score: Total score = Clinical + PFT + CXR – Complications. A full description of the scoring method can be found in File S1.

Measures of lung function
At baseline (n = 52) and at all defined time points during PEs (n = 8–13), lung function was assessed by spirometry, and included FEV1 (% and FVC%). Spirometry was performed according to the American Thoracic Society standards[18,19].

Patient reported quality of life (QOL)
The QOL evaluation was recorded at baseline (n = 52) and at defined time points during PE (n = 8–13) by a self-administered questionnaire using the CF Questionnaire-Revised (CFQ-R) which comprised of 50 items associated with 3 symptom scales (Weight, Respiratory Function and Digestion) and 9 QOL domains (Physical, Vitality, Emotional, Eating Disturbances, Treatment Burden, Health Perceptions, Body Image, Social Functioning and Role/School Functioning) [20]. Higher scores reflect healthier disease status. The total score is the sum of scores for all items in the questionnaire.

Plasma inflammatory biomarker analysis
At baseline (n = 52) and each defined time points during PEs (n = 8–13), blood samples were collected in ethylenediaminetetraacetic acid (EDTA) coated tubes and spun at 3000 rpm for 10 min at 4 °C for plasma isolation. Plasma CRP levels were quantified in the hospital’s clinical laboratory using ELISA. Cytokines were measured in plasma with the MILLIPLEX® Map multiplex assay kit (Millipore, Mississauga, ON, Canada) and the MAGPIX® multiplex system (Millipore) according to the manufacturer’s instructions. The data was assessed for interleukin (IL)-1β, IL-6, IL-8, IL-10, macrophage inflammatory protein 1β (MIP-1β, also known as CCL4), tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) using the MILLIPLEX® Analyst software, version 4.2 (Millipore). The concentrations of cytokines are expressed as pg/ml.

Plasma polyunsaturated fatty acid and lipid peroxidation analysis
After plasma isolation as described above, 100 µl of plasma was added to 900 µl 2:1 chloroform/methanol solution with added 1 mM of butylated hydroxyanisole (BHA) to prevent oxidation of the fatty acids. Samples were stored in −80 °C until analysis. Lipids were isolated using the method described by Folch [21]. The polyunsaturated fatty acids (PUFA) in this fraction were esterified by gas chromatography/mass spectrometry (Hewlett Packard 5880A, WCOT capillary column Supelco-10, 33 m × 0.5 mm, 1 µm thick) using commercial standards (Sigma-Aldrich, Oakville, ON, Canada)[23]. In addition, the total protein content of the aqueous phase was analysed using the bicinchoninic acid (Pierce Biotechnology, Rockford, IL, USA). The concentrations of arachidonic acid (AA) and docosahexaenoic acid (DHA) are expressed as nmol/µg of protein. The AA/DHA ratio represents the amount of AA to DHA in each patient. The AA/DHA ratio represents the amount of AA to DHA in each sample. Lipid peroxidation was assessed by indirectly measuring malondialdehyde (MDA) using the thiobarbituric acid reactive species (TBARS) assay[23] and is expressed as nmol of TBARS/mg of protein.

Statistical analysis
The Cox proportional hazards and Kaplan-Meier models were used for survival analysis with time to first PE used as the outcome. For the Cox proportional hazards models, models were adjusted for age and sex. For the Kaplan-Meier method, continuous covariates were dichotomized at the median, and a log rank test was conducted (Figure 1). For comparisons of two groups, the Student’s t-test or the Mann-Whitney test and Chi-square were used. For changes from baseline during PE, statistical analysis was performed using the percentage change with the one sample t-test or Wilcoxon signed-rank test (Figures 2 and 3, Table S1). The percentage change was calculated as: (Value PE time point – Value baseline)/Value baseline × 100.

The ANOVA test with Bonferroni post-tests were used to evaluate differences between the PUFA levels at all PE time points (Figure 4) and Pearson correlations were estimated for this data. Significance was set at p<0.05. See File S1 for additional description.

Results

Patient demographics, baseline clinical and biomarker characteristics
We prospectively followed our adult CF cohort for a total of 24 months, and 37 out of 52 patients experienced at least one PE during the follow-up period. The patient demographics and baseline values of the cohort are described in Tables 1 and 2. At baseline, CF patients that experienced at least one PE (“PE group”) had lower lung function, weight, BMI and Matouk Disease Score compared to the patients who did not have a PE (“no PE group”) (Table 1). The baseline levels of white blood cells and blood neutrophils, although still within the normal range, were higher in the “PE group”, suggesting higher levels of systemic inflammation even during a stable disease state. These patients also had lower QOL assessments for total score, Weight, Physical, Emotion, Health Perceptions, Body Image and Role items (Table 1). IL-6 and IL-10 levels were higher in the “PE group” compared to the “no PE group” (Table 2). Consistent with previously reported data from our group and other investigators [24-26] there was a lipid imbalance in PUFA with high AA levels and low DHA levels CF patients compared to HC. Overall the AA/DHA ratio was higher in CF patients than in HC. However, there were no differences in fatty acids between the “no PE group” and “PE group” during stable disease. Overall, these characteristics suggest that the “PE group” has more severe and active disease, and a lower QOL at baseline, compared the “no PE group”.

Worse clinical disease severity and activity, and QOL are associated with PE events
Using the Cox proportional hazards model adjusting for age and sex, we tested the association between our markers and the risk of PE (Table 3). Better lung function (FEV1, % and FVC%) and higher Clinical, PFT, CXR subscores and total Matouk Disease Score were associated with a lower risk of PE. A lower Complications subscore was associated with lower risk of PE. The Matouk Disease Score incorporates patients’ symptoms as well as physician-recorded clinical parameters and other complications adding to disease activity beyond spirometric evaluations. Thus a high degree of disease severity as measured by lung spirometry was associated with high risk of PE as was high disease severity and activity.
activity assessed by the Matouk Disease Score. The analysis also showed that low CFQ-R symptom scores (Weight and Respiratory) and low QOL domains (Physical, Vitality, Health Perceptions and Role) indicated higher risk of PE. No inflammatory markers or PUFA were found to be associated with risk of PE using the Cox proportional hazard model.

To illustrate these relationships, we used the Kaplan-Meier survival model, with patients dichotomized based on median values (Figure 1). We obtained similar results to the Cox proportional hazards model. Lower lung function (FEV1% predicted, Figure 1A and FVC%, Figure 1B), worse subscores of the Matouk Disease Score (low Clinical subscore, Figure 1C and high Complications subscore Figure 1D, data not shown for other domains), higher FEV1% predicted (p = 0.020), higher FVC% predicted (p = 0.032), higher Clinical subscore of the Matouk Disease Score (p = 0.004), lower Complications subscore of the Matouk Disease Score (p = 0.000), higher assessments of QOL physical (p = 0.030) and higher health perceptions (p = 0.006) domains.
subscores) and low scores for the CFQ-R QOL domains Physical and Health Perceptions were also related to a higher risk of a future PE (Figures 1E and 1F, respectively). No baseline inflammatory markers or PUFA were associated with increased risk of PE events, although there was a trend with higher CRP levels (median 5.3 mg/L, p = 0.0537, data not illustrated).

Changes in clinical parameters and QOL during PE

We performed a second study with 13 patients to evaluate whether any of our markers at the end of PE treatment would be predictive of an early re-exacerbation. We first calculated the percentage change at each time point for each patient compared to their baseline values obtained during a period of stable disease (Figure 2 and full data set is presented in Table S1). As expected, lung function was most reduced at Day 1 of a PE (−16.8% FEV1% and −16.1% FVC% compared to baseline), and steadily improved over the course of PE treatment lasting either 14 or 21 days (Figure 2A). FEV1% and FVC% approached pre-PE baseline values at Day 14. However, both values decreased again by Day 21 and 42 where FVC% values were 10.5% lower than baseline values (p = 0.028) (Figure 2A). At the onset of PE (Day 1), all components of the Matouk Disease Score worsened compared to baseline (Clinical subscore illustrated in Figure 2A). The Clinical subscore steadily improved with PE treatment where it was 3.4% above baseline on Day 21. The CXR subscore did not decrease at PE onset, however showed a trend toward improvement on Day 21, attesting to the limited sensitivity of the Bradsfield radiologic scoring to capture small CXR changes (Table S1). The QOL evaluation revealed that patients recognized a decline of their health on Day 1 with improvements on Days 7, 14, 21 and 42 (Respiratory, Physical and Health Perceptions illustrated in Figure 2B).

Changes in inflammatory markers during PE

In previous studies, inflammatory markers such as CRP, IL-1β, IL-6, IL-8 and VEGF were found to increase with PE onset and to respond to antibiotic treatment for PEs [14,15,27–32]. We calculated the percentage change for the concentrations of

![Figure 2. Percentage change of clinical and QOL parameters throughout PEs in CF. A) FEV1% (blue, circles) and FVC% (red, squares) were significantly reduced from baseline values at Day 1 of PE (FEV1% p = 0.001; FVC% p = 0.010). Both parameters subsequently improved with treatment however, FVC% significantly declined at Day 42 (p = 0.028). The Clinical subscore of the Matouk Disease score (green, triangles) was significantly decreased from baseline values on Day 1 (p = 0.000) and Day 7 (p = 0.045). See Table S1 for the results of other Matouk Disease subscores. B) QOL items also decreased with PE onset, Day 1, such as Respiratory (blue, circles, p = 0.002), Physical (red, squares, p = 0.025) and Health Perceptions domains (green, triangles, p = 0.000). The Physical and Health Perceptions domains remained decreased at Day 7 (p = 0.025 and p = 0.001, respectively). Other QOL domains which decreased at Day 1 include: Vitality, Health Perceptions, Social and Role (Table S1). The dotted horizontal line indicates a 0% change or no change from baseline values. * indicates a significant difference from baseline. Day 1, n = 13; Day 7, n = 12, Day 14, n = 11; Day 21, n = 9; Day 42, n = 8. Full table of results can be found in Table S1. doi:10.1371/journal.pone.0088567.g002]
inflammatory markers at each time point, in comparison to baseline values for each patient. In general, we also found PE onset induced an inflammatory response which returned to baseline values toward the end of treatment (Days 14 and 21). Once off aggressive treatment for PE, inflammatory markers tended to increase again in some patients at Day 42. More specifically, we found the elevated CRP levels from baseline values on Day 1 decreased during treatment and significantly worsened once again post-treatment by Day 42 (Figure 3A). Similarly, IL-6, IL-8, MIP-1β and VEGF also increased on Day 1 and improved over the course of treatment (Figure 3B, C, E, F, respectively). IL-10 increased on Days 7 and 14 from baseline values, suggesting that anti-inflammatory mechanisms were activated (Figure 3D). Interestingly, MIP-1β levels significantly increased again post-treatment on Day 42 (Figure 3F). All other inflammatory markers tended to increase at Day 42, although with a large variation between patients. IL-1β and TNF were not significantly changed throughout PE (Table S2).
Improvements in PUFA levels and lipid peroxidation during PE

A hallmark of CF disease is the imbalance in PUFAs with high levels of AA and low levels of DHA [24-26,33,34]. AA is pro-inflammatory and its metabolites include prostaglandins and eicosanoids which are also increased in CF [35,36]. DHA is anti-inflammatory and its metabolites include resolvins and protectins. This imbalance in PUFAs may contribute to the inflammatory status observed in CF [37,38]. In fact, our previous studies in a CF mouse model showed improvements in AA and DHA after treatment with fenretinide, a semi-synthetic retinoid, which were concurrent with reductions in inflammatory markers and better clearance of lung infections [25,39].

Unexpectedly, we found improvements in the PUFA imbalance compared to baseline on Day 21 for both AA (Figure 4A) and DHA (Figure 4B). At this time point, AA levels dropped to normal values, the AA/DHA ratio improved (Figure 4C), and both were no longer significantly different from HC concentrations. It is important to note that these improvements were not permanent as AA levels and AA/DHA ratios increased by Day 42. Lipid peroxidation decreased with treatment for PE and, MDA levels were no longer different from HC at Day 21 (Figure 4D). We found a significant positive correlation between MDA and AA in plasma at the end of treatment ($r = 0.6917$, $p = 0.013$) and an inverse correlation between MDA and DHA, however this trend did not reach significance ($r = -0.3392$, $p = 0.290$).

Potential promising markers of early re-exacerbation

To determine whether any of our markers assessed on the last day of treatment (either Day 14, $n = 4$, or Day 21, $n = 8$) could indicate an early re-exacerbation, the patient cohort was divided based on whether their next PE was under or over 42.5 days from the last day of treatment, which was the median number of days for the group (Table 4). “Early PE” refers to the patient group which had their next PE less than 42.5 days after the last day of treatment, while the group which developed no subsequent PE or a second PE more than 42.5 days after the last day of treatment was called “Late PE”. One patient was excluded from the analysis since information on their next PE was not available, thus 12 patients were included. The “Early PE” group had a trend towards lower lung spirometry values, total Matouk Disease Score and QOL total score at end of treatment compared to the “Late PE” group, but this did not result in a statistical significance. More importantly, we found increased levels of inflammatory markers in...
“Early PE” patients with significantly higher CRP and IL-8, indicating that these markers may contribute to assessing which patients could rapidly re-exacerbate.

**Discussion**

The importance of PEs in CF disease progression is well established however the triggers of these events are still being understood which limits the means for prevention. Retrospective studies have identified patient groups at risk of PEs such as those with liver disease, CF related diabetes, low FEV1 values [5,12]. However, the difficulty remains in determining on an individual basis which patient has a high risk of a future PE.

Our prospective study is unique for two main reasons: 1) the large panel of data that were collected at stable disease and 2) the extensive sampling throughout PEs. With these results, we assessed markers predicting future PE in two distinct cases: from stable disease and at the last day of treatment for PE.

**Assessing risk from stable disease**

Patients who developed PEs had worse baseline disease severity (based on lung spirometry and BMI), greater baseline disease activity (based on the Matouk Disease Score) and worse self-reported QOL at stable disease. Interestingly, this was associated with higher inflammatory markers [58x279] when values were not normally distributed. NR indicates normal range for cell counts. BMI normal range from Health Canada (http://www.hc-sc.gc.ca). doi:10.1371/journal.pone.0088567.t001

| Table 1. Patient demographics and baseline values of studied parameters. |
|---------------------------------------------------------------|
| **Demographics** | **Total CF patient group** | **Non-exacerbating (no PE)** | **Exacerbating (PE)** | **p-value no PE vs. PE** |
|-------------------|----------------------------|------------------------------|----------------------|-------------------------|
| Number of patients | 52 | 15 | 37 |
| **Sex (F/M)** | 24/28 | 5/10 | 19/18 | 0.358 |
| **Age** | 32.8 (1.8) | 36.1 (3.4) | 31.5 (2.3) | 0.112 |
| **Age range** | 18-64 | 18-59 | 18-64 |
| **Weight (kg)** | 60.8 (2.1) | 64.9 (2.8) | 59.1 (2.6) | 0.031* |
| **BMI (kg/m²) (NR: 18.5–24.9) | 21.9 (0.6) | 23.4 (0.7) | 21.3 (0.7) | 0.009* |
| **Clinical assessments** | **FEV1% predicted (%) | 63.0 (3.8) | 78.5 (5.0) | 56.8 (4.6) | 0.009* |
| **FVC% predicted (%) | 79.8 (3.7) | 95.1 (5.2) | 73.6 (4.4) | 0.008* |
| **White blood cells (10⁹/L (NR: 4.8–10.8) | 9.4 (0.4) | 8.1 (0.6) | 10.0 (0.4) | 0.018* |
| **Neutrophils (10⁹/L (NR: 1.6–7.7) | 6.7 (0.3) | 5.6 (0.5) | 7.1 (0.4) | 0.033* |
| **Eosinophils (10⁹/L (NR: 0.0–0.5) | 0.2 (0.02) | 0.2 (0.07) | 0.2 (0.01) | 0.562 |
| **Platelets (10⁹/L (NR: 140–440) | 284.6 (8.4) | 244.0 (14.6) | 301.6 (9.0) | 0.001* |
| **Matouk Disease Score** | Clinical (0–50 points) | 36.3 (0.6) | 39.3 (1.0) | 35.1 (0.7) | 0.002* |
| **PFT (0–25 points) | 16.6 (0.9) | 19.9 (1.1) | 15.2 (1.0) | 0.018* |
| **CXR (0–25 points) | 16.5 (0.4) | 18.2 (0.9) | 15.8 (0.4) | 0.008* |
| **Complication (0–37 points) | 2.6 (0.5) | 0.3 (0.2) | 3.5 (0.7) | 0.000* |
| **Total (0–1200 points) | 66.9 (2.0) | 77.3 (2.3) | 62.6 (2.4) | 0.001* |
| **Quality of life** | **Weight** | 64.1 (5.2) | 84.5 (5.5) | 55.9 (6.5) | 0.016* |
| **Respiratory** | 68.3 (2.3) | 74.8 (4.5) | 65.6 (2.6) | 0.072 |
| **Digestion** | 78.0 (2.5) | 84.5 (4.0) | 75.4 (3.1) | 0.064 |
| **Physical** | 71.8 (3.4) | 83.3 (3.8) | 67.2 (4.4) | 0.041* |
| **Vitality** | 64.4 (2.2) | 67.8 (4.4) | 63.1 (2.6) | 0.341 |
| **Emotion** | 81.7 (2.2) | 90.7 (2.6) | 78.0 (2.7) | 0.008* |
| **Eating** | 90.3 (2.3) | 91.1 (4.8) | 89.9 (2.7) | 0.537 |
| **Treatment burden** | 66.2 (3.4) | 74.8 (6.7) | 62.8 (3.9) | 0.113 |
| **Health Perceptions** | 69.5 (2.8) | 80.8 (4.0) | 54.9 (3.3) | 0.009* |
| **Body Image** | 73.5 (3.5) | 88.9 (3.1) | 67.3 (4.3) | 0.004* |
| **Social** | 74.6 (2.5) | 81.5 (4.4) | 71.8 (2.9) | 0.074 |
| **Role** | 82.8 (2.8) | 91.7 (3.0) | 79.2 (3.6) | 0.044* |
| **Total (0–1200 points) | 885.2 (2.18) | 994.2 (28.9) | 841.0 (25.1) | 0.001* |

Data represented as mean (SEM). * p-value designates significant statistical difference between non-exacerbating (no PE) and exacerbating patients (PE) using Student’s t-test or Mann-Whitney t-test when values were not normally distributed. NR indicates normal range for cell counts. BMI normal range from Health Canada (http://www.hc-sc.gc.ca).

doi:10.1371/journal.pone.0088567.t001
Presently, there are no known methods which could prevent the occurrence of PEs. Current treatments for CF have shown impacts on reducing the number of PEs, such as routine inhaled antibiotic therapy for infected patients, human recombinant deoxyribonuclease and inhaled hypertonic saline [40]. Some CF centers advocate the routine use of IV antibiotics for two weeks every three months, rather than in only response to PE symptoms. They report improved survival rates using this protocol, however its impact on the rate of PEs is unclear [41,42]. Elborn et al. reported no significant effect of elective IV antibiotics every three months (four/year) in a randomized control trial compared to treating patients because of PEs. Patients in the control group were prescribed IV antibiotics three times per year while 40% of the elective treatments were in response to PEs. Thus it is unclear whether elective IV antibiotics had a significant impact on reducing the rate of PE [43,44]. However, the number of PEs in each group were not directly compared, thus based on the reports currently available, it is difficult to conclude whether the rate of PEs can be reduced by preventative aggressive antibiotics. These treatments were assigned at specific times (every three months) which may come too early to prevent PEs. Rather patients may benefit from obtaining IV antibiotics as soon as a change is detected in their clinical status or QOL assessments. Previous studies have shown that CF patients who recorded their lung spirometry using a daily diary had lower rates of lung function decline than those who did not [45]. A new study by Lechtzin et al. looking at twice weekly electronic symptom recording by CF patients may help determine the usefulness of a more frequent symptom and lung function monitoring for early recognition of PEs [7].

### Table 2. Baseline values of inflammatory markers and fatty acids.

| Marker       | Healthy controls (HC) n = 3–11 | Total CF patients group (CF) n = 52 | Non-exacerbating CF patients (no PE) n = 15 | Exacerbating CF patients (PE) n = 37 |
|--------------|--------------------------------|------------------------------------|--------------------------------------------|--------------------------------------|
| CRP (mg/L)   | 2.0 (1.1)                      | 7.4 (1.0)                          | 6.04 (1.7)                                  | 8.0 (1.2)                            |
| IL-1β (pg/ml)| 3.8 (2.7)                      | 0.9 (0.1)                          | 0.79 (0.2)                                  | 0.9 (0.1)                            |
| IL-6 (pg/ml) | 3.7 (2.1)                      | 5.2 (1.2)                          | 2.93 (0.6)                                  | **6.0 (1.6)**                        |
| IL-8 (pg/ml) | 3.6 (0.9)                      | 5.5 (0.5)                          | 4.08 (0.6)                                  | 5.8 (0.6)                            |
| IL-10 (pg/ml)| 2.1 (0.9)                      | **29.1 (3.2)**                     | 19.04 (2.6)                                  | **38.8 (7.2)**                       |
| MIP-1β (pg/ml)| 31.8 (6.9)                     | 24.3 (1.6)                         | 24.83 (3.2)                                  | 24.2 (1.9)                           |
| TNF (pg/ml)  | 5.3 (0.5)                      | **3.8 (0.3)**                      | 3.45 (0.5)                                  | 3.9 (0.4)                            |
| VEGF (pg/ml) | 129.5 (46.7)                   | 95.7 (16.5)                        | 82.45 (17.3)                                 | 101.0 (22.2)                         |
| AA (nmol/µg of protein) | 37.0 (2.4)                     | **49.5 (0.8)**                     | 48.45 (1.5)                                  | 49.9 (1.0)                           |
| DHA (nmol/mg of protein) | 2.7 (0.1)                     | **1.2 (0.1)**                      | 1.30 (0.1)                                  | 1.2 (0.1)                            |
| AA/DHA ratio | 14.4 (1.4)                     | **48.8 (4.6)**                     | 40.92 (3.8)                                  | 51.8 (6.1)                           |

Data represented as mean (SEM). * p-value represents statistically significant difference between HC and CF groups. † represents statistically significant difference between “no PE” and “PE” groups. Significance was set at p < 0.05.

doi:10.1371/journal.pone.0088567.t002

### Table 3. Markers influencing time to first PE during stable disease.

| Marker                  | Hazard ratio1   | 95% hazard ratio confidence limits | p-value |
|-------------------------|-----------------|-----------------------------------|---------|
| Clinical assessment     |                 |                                   |         |
| FEV1% predicted         | 0.97            | 0.94–0.99                         | 0.006   |
| FVC% predicted          | 0.97            | 0.95–0.99                         | 0.010   |
| Matouk Disease Score    |                 |                                   |         |
| Clinical                | 0.74            | 0.63–0.86                         | 0.000   |
| PFT                     | 0.88            | 0.80–0.98                         | 0.015   |
| CXR                     | 0.71            | 0.50–0.94                         | 0.017   |
| Complication            | 1.33            | 1.17–1.51                         | 0.000   |
| Total                   | 0.92            | 0.88–0.96                         | 0.000   |
| Quality of life         |                 |                                   |         |
| Weight                  | 0.97            | 0.95–0.99                         | 0.006   |
| Respiratory             | 0.96            | 0.92–0.99                         | 0.024   |
| Physical                | 0.96            | 0.93–0.99                         | 0.003   |
| Vitality                | 0.96            | 0.93–1.00                         | 0.043   |
| Health perceptions      | 0.95            | 0.92–0.99                         | 0.005   |
| Role                    | 0.96            | 0.94–0.99                         | 0.020   |
| Total                   | 0.99            | 0.99–1.00                         | 0.004   |

1 HR<1 is associated with lower risk of future PE.
Prediction from end of treatment
Each PE significantly decreases lung function in CF patients, even more with PEs in rapid succession [4]. In our study, we found that higher inflammation at the end of treatment may be a better indication of early re-exacerbation rather than clinical or patient QOL assessments (Table 4). The few prospective studies looking at predictors of future PEs used measurements at the end of PE treatment. CRP was previously shown to be correlated to the number of days until the next PE [14], a finding not universally reported [15]. Regardless of the discrepancies, these studies showed the usefulness of inflammatory markers such as CRP and calprotectin in assessing risk of future PE [14,15]. Sequeiros et al. also showed that early re-exacerbation was correlated with more symptoms after 14 days of treatment such as cough, sputum production, breathlessness and fatigue [14]. We found that FEV1% values tended to be lower in patients that quickly re-exacerbated, and due to our small patient group, we cannot disregard this as a marker of recurring PE. Thus, inflammatory markers such as CRP and IL-8, in conjunction with patient reported symptoms, clinical evaluations and spirometry, could be additional indicators of a recurring PE. And, although symptoms and clinical picture (lung function and Matouk Disease score) have returned to baseline at the end of treatment, patients may still be experiencing some level of unresolved inflammation indicating the PE has not been cleared completely. There has been evidence that extending the course of antibiotics may only offer a small improvement in symptoms but not lung function or QOL assessments (Table 4). The few prospective studies looking at predictors of future PEs used measurements at the end of PE treatment. CRP was previously shown to be correlated to the number of days until the next PE [14], a finding not universally reported [15]. Regardless of the discrepancies, these studies showed the usefulness of inflammatory markers such as CRP and calprotectin in assessing risk of future PE [14,15]. Sequeiros et al. also showed that early re-exacerbation was correlated with more symptoms after 14 days of treatment such as cough, sputum production, breathlessness and fatigue [14]. We found that FEV1% values tended to be lower in patients that quickly re-exacerbated, and due to our small patient group, we cannot disregard this as a marker of recurring PE. Thus, inflammatory markers such as CRP and IL-8, in conjunction with patient reported symptoms, clinical evaluations and spirometry, could be additional indicators of a recurring PE. And, although symptoms and clinical picture (lung function and Matouk Disease score) have returned to baseline at the end of treatment, patients may still be experiencing some level of unresolved inflammation indicating the PE has not been cleared completely. There has been evidence that extending the course of antibiotics may only offer a small improvement in symptoms but not lung function or inflammation [46]. In these cases, perhaps a change in antibiotics and/or the use of anti-inflammatory agents to aid in the resolution of inflammation would benefit the patient and prevent early re-exacerbation. However, based on our study, we cannot determine whether the unresolved inflammation itself triggers a new PE or whether it is a response to other underlying active processes such as a poorly controlled infection. We did not look at causes of PEs such as viral infections which have been reported to impact recovery from PE [9].

Kinetics of inflammation and PUFA throughout PE
We found in general inflammatory markers increased at PE onset such as CRP, IL-6, IL-8, MIP-1β and VEGF compared to values at stable disease periods, and responded to treatment as soon as Day 7 (Figure 3). This corroborates previous findings regarding resolution of inflammation with antibiotic treatment [14,27,32,47]. MIP-1β, a chemoattractant for monocytes, has rarely been assessed in CF and, to our knowledge, this is the first time reported to respond to treatment in the context of PEs in CF.

Our study design allowed us to monitor whether improvements during PE treatment are maintained after treatment was completed. Five patients out of 13 were not available for Day 42 assessments due to a re-exacerbation (n = 4) or other complications (n = 1, same patient that was excluded from the second study on markers associated with early re-exacerbation). Even with this small number of patients, we were able to observe decreases in FVC% values and increases in CRP and MIP-1β at Day 42 compared to baseline values. Due to the small sample size and large variation at this time point, we could not conclude whether these changes are indicative of future exacerbations and further studies are necessary. However, it is important to recognize that improvements at the end of treatment, a time point assessed in many PE studies, may not be representative of the patient’s disease status on the long term.

Few studies have assessed the changes in PUFAs at PE onset and throughout treatment [48,49]. Similar to our results regarding lipid peroxidation, McGrath and colleagues demonstrated a decrease MDA in CF patients after antibiotic treatment for PE [50]. The improvements in PUFA during PE occur during treatment but worsen at Day 42, when patients are no longer treated for PE. Thus the improvements in the AA/DHA ratio may be due to the effects of the treatment itself in reducing lipid peroxidation, also observed in this study. Antibiotics have been shown to protect lung epithelial cells from oxidative damage [51]. Tobramycin in particular was found to act as a potent reactive oxygen species scavenger [52]. In general, PUFAs are very susceptible to peroxidation due to their high content of double bonds compared to other types of fatty acids causing DHA to be more affected than AA [53]. The increase in anti-inflammatory DHA may contribute to the resolution of inflammation. Additionally, the reduction in lipid peroxidation may itself be a factor. Oxidized fatty acids such as DHA were found to act on Toll-Like Receptor 4 much like its ligand lipopolysaccharide activating downstream NF-κB signalling [54]. It is important to note that changes in PUFA were not permanent and routine treatments for disease maintenance do not normalize PUFA levels since CF patients at stable disease still have defects in AA and DHA levels (Figure 4 and Table 2). Currently, no antibiotic or steroid therapy for CF has proven to be successful in correcting
PUFA abnormalities, which could improve disease status of patients.

Limitations

Our study has several limitations that are important to consider. Among the 52 patients included in our analysis, we had longitudinal clinical and molecular marker measurements in only 13 patients during their PEs. Due to the extensive testing and the availability of the clinical coordinator, this was the volume of patients we could handle for the study period. However, due to the large panel of markers we assessed and the prospective nature of the study design, this study remains an important exploratory analysis generating many hypotheses about predictive markers of PE.

The median time to next PE was somewhat low suggesting that our patient group had high disease activity. Parkins et al. described that 13% of their patient cohort re-exacerbated in 45 days. They used this time point as a definition of non-response to treatment which may be another way to describe the six patients with early re-exacerbations since they had higher levels of inflammation[1]. Our Day 42 time point was also affected when it overlapped with new PEs. Noteworthy, our definition of PE was more inclusive than the other definitions used[5,14,27] as it included any event needing additional IV or oral therapy thereby including mild and severe types of exacerbations.

Conclusions

This study demonstrates that monitoring changes in clinical and patient reported assessments during stable disease may help in determining which patients are at risk for PE. Our longitudinal analysis of inflammation throughout PEs suggests that, at the end of antibiotic treatment for PE, inflammatory markers could contribute to monitoring patients at risk of early recurring PE. The imbalance in PUFA levels improve after treatment for PE possibly due to a decrease in lipid peroxidation. Regarding early re-exacerbation, our analysis reveals that CRP and IL-8 in particular can be important in assessing patients at risk of early recurring PEs, which needs to be confirmed in a larger study. The data presented here offer more insight into potential markers of PEs which, in conjunction with clinical data, may improve earlier recognition of PEs in CF.

Supporting Information

Table S1 Percentage change of clinical parameters throughout exacerbations in CF. Includes percentage change, standard errors and statistical evaluation of clinical parameters, Matouk Disease Score and QOL assessments throughout PE time points. (DOCX)

Table S2 Percentage change of inflammatory markers during PE. Includes percentage change, standard errors and statistical evaluation of inflammatory markers throughout PE time points. (DOCX)

Acknowledgments

We would like to thank all the personnel at the Adult Cystic Fibrosis Clinic at the Montreal Chest Institute, all the patients and healthy volunteers participating in this study.

Author Contributions

Conceived and designed the experiments: GW HGA JG JL LCL DN SR. Performed the experiments: GW. Analyzed the data: GW AB. Contributed reagents/materials/analysis tools: JBS SR DR. Wrote the paper: GW DR. Clinical assessments of patients: J. Bernier EM. Administration of quality of life questionnaire: J. Bernier. Blood sample processing: J. Berube.

References

1. Parkins MD, Rendall JC, Elborn JS (2012) Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141: 485–493.
2. Sanders DB, Ritter RC, Rosenfeld M, Hoffman LR, Redding GJ, et al. (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182: 627–632.
3. Liu TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, et al. (2001) Predictive 3-year survivorship model of cystic fibrosis. Am J Epidemiol 153: 345–352.
4. Waters V, Stanojevic S, Avenafu KG, Lu A, Yao Y, et al. (2012) Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 40: 61–66.
5. de Beer K, Vandenheuvel KL, Tullia E, Doucette S, Ferguson D, et al. (2011) Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 66: 680–683.
6. Hakimi Shoki A, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS (2013) Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Chest epub Jul 18.
7. Lechzin N, West N, Allgood S, Wilhelm E, Khan U, et al. (2015) Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (4ICE) trial. Contemp Clin Trials 36: 460–469.
8. Hoek RA, Paats MS, Pas SD, Bakker M, Hoogsteden HC, et al. (2013) Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis 45: 63–69.
9. Etherington C, Naseer R, Conway SP, Whitaker P, Denton M, et al. (2013) The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J Cyst Fibros epub Jul 23.
10. Farhat SC, Almeida MB, Silva-Filho LV, Farhat J, Rodrigues JC, et al. (2013) Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis. Chest 144: 1186–1192.
11. Fodor AA, Kleen ER, Gilpin DF, Elborn JS, Boucher RC, et al. (2012) The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 7: e54001.
12. Savicki GN, Ayyagari R, Zhang J, Signorovitch JE, Fan L, et al. (2013) A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol 48: 954–961.
13. Sutton S, Rosenbluth D, Raghavan D, Zheng J, Jain R (2013) Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol epub Mar 4.
14. Sequeiros EM, Jarad N (2012) Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 9: 9–16.
15. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, et al. (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 9: 193–198.
16. Mateouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K (1997) Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J 10: 2004–2013.
17. Mateouk E, Ghezzo-RH, Gruber J, Hidvegi R, Gray-Donald K (1999) Construct and longitudinal validity of a modified Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J 13: 552–559.
18. Society AT (1987) Standardization of Spirometry, a Statement of the American Thoracic Society. Am Rev Respir Dis 136: 1293–1298.
19. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1985) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725–734.
Markers of Exacerbations in Cystic Fibrosis

20. Quitter AL, Sweet E, Wauters M, Munzenberger P, Baux K, et al. (2000) Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 25: 403–414.

21. Folch J, Lees M, Stanely GE (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497–509.

22. Schlenk H, Gellerman J (1960) Estimation of fatty acids with diazomethane on a small scale. Anal Chem 32: 1412–1414.

23. Oborna I, Wojewodka G, De Sanctis JB, Fingerova H, Svobodova M, et al. (2010) Increased lipid peroxidation and abnormal fatty acid profiles in seminal and blood plasma of normozoospermic males from infertile couples. Hum Reprod 25: 308–316.

24. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, et al. (2004) Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350: 560–569.

25. Guilbault C, Wojewodka G, Saeed Z, Hajducz M, Matouk E, et al. (2008) Cystic Fibrosis Fatty Acid Imbalance is Linked to Ceramide Deficiency and Corrected by Fenretinide. Am J Respir Cell Mol Biol 41: 100–106.

26. Gilljam H, Strandvik B, Ellis A, Wiman LG (1986) Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest 46: 511–518.

27. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, et al. (2013) Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 68: 532–539.

28. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS (2007) The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 42: 729–735.

29. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ (1998) Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 157: 1764–1769.

30. Liou TG, Adler FR, Koegh RH, Li Y, Jensen JL, et al. (2012) Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One 7: e42748.

31. Chiron R, Grumbach YY, Quynh NV, Verriere V, Urbach V (2008) Lipoxin A4 and interleukin-1β levels in cystic fibrosis sputum after antibiotic therapy. J Cyst Fibros 7: 463–468.

32. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, et al. (2005) Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 40: 15–21.

33. Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, et al. (2006) Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22: 36–46.

34. Strandvik B, Bromegard M, Gilljam H, Carlsted-Duke J (1988) Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. Scand J Gastroenterol Suppl 143: 1–4.

35. Konstan MW, Walenga RW, Hillaire KA, Hilliard JB (1993) Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 148: 896–901.

36. Lucidi V, Clabauttoni G, Bella S, Barnes PJ, Moutusch P (2008) Exhaled f2-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. Free Radic Biol Med 45: 913–919.

37. Lawrence RH, Sorrell TC (1994) Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin Exp Immunol 98: 12–16.

38. Welsh SM, Mullin AG, Loscher CE, Hurley LA, Roche HM (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide–stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18: 250–256.

39. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, et al. (2008) Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 38: 47–56.

40. Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, et al. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176: 957–969.

41. Szaff M, Hooby N, Flensborg EW (1983) Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 72: 651–657.

42. Nir M, Lanug S, Johannsen HK, Koch C (1996) Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre. Thorax 51: 1023–1027.

43. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, et al. (2000) Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55: 355–358.

44. Breen L, Awamn N (2012) Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 7: CD002767.

45. Finkelstein SM, Wielinski CL, Kujawa SJ, Loewenson R, Warwick WJ (1992) The impact of home monitoring and daily diary recording on patient status in cystic fibrosis. Pediatr Pulmonol 12: 3–10.

46. Sequeiros IM, Jarad NA (2012) Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 9: 213–220.

47. McCoyd SA, Stellnach V, Boas SR, Jain M, Crawford SE (2000) Serum vascular endothelial growth factor is elevated in cystic fibrosis patients and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 161: 1877–1880.

48. Durieu I, Abbas-Chorfa F, Drat J, Ijarz J, Stephens JP, et al. (2007) Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis. Eur Respir J 29: 958–964.

49. Durieu I, Vericel E, Guichardant D, Roth H, Stephens JP, et al. (2007) Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study. J Cyst Fibros 6: 320–326.

50. McGrath LT, Mallon P, Dowey L, Silke B, McClean E, et al. (1999) Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 54: 518–523.

51. Cantin A, Woods DE (1993) Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 91: 38–45.

52. Gzin I, MacGregor HJ, Nevell TG, Mason T, Laight D, et al. (2013) Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity. Br J Pharmacol 168: 1165–1181.

53. Halliwel B, Chirico S (1993) Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 57: 715S–728S.

54. Mutoh A, Ueda S (2013) Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells. Life Sci 92: 984–992.